source: American Society of Clinical Oncology
authors: Ray Comenzo, Efstathios Kastritis, Mathew Maurer, Jeffrey A. Zonder, Monique Minnema, Stefan Schönland, Ashutosh Wechalekar, Giovanni Palladini, Xiang Qin, Sandra Y. Vasey, Imran Khan, Jordan Mark Schecter, Giampaolo Merlini summary/abstract:
Systemic AL amyloidosis is characterized by disposition of insoluble amyloid fibrils into tissues and organs via clonal expansion of CD38+ plasma cells. The safety run-in of DARA SC + CyBorD in ANDROMEDA (NCT03201965) is presented.
Eligible pts had >=1 involved organs, ECOG score =<2, absolute neutrophil count >=1.0 × 109/L; hemoglobin >=8.0 g/dL; platelet count >=50 × 109/L; estimated glomerular filtration rate >=20 mL/min/1.73m2, and NT-ProBNP =<8,500 ng/L. In the safety run-in, pts received a concentrated co-formulation of DARA (1,800 mg in 15 mL) and recombinant human hyaluronidase enzyme (rHuPH20; 30,000 U) in a single, pre-mixed vial, given by manual SC injection qw in Cycles 1-2, q2w in Cycles 3-6, and q4w thereafter =<2 y. Cy 300 mg/m2 PO or IV and Bor 1.3 mg/m2 SC were given on Days 1, 8, 15, 22 of each 28-day cycle for =<6 cycles and D 40 mg was given qw. Dosing was staggered >=48 hours between pts to assess infusion related reactions (IRRs). Safety was evaluated after >=10 pts received >=1 treatment cycle.
Pts (n = 15) had a median (range) age of 63 (35-77) y and a median of 58 (15-157) d from diagnosis. Pts had a median of 1 (1-3) involved organ, with kidney involvement affecting 67% of pts and 40% of pts with >=2 organs involved. At baseline, 73% and 27% of pts were grouped into New York Heart Association class I and II, respectively, and 93% of pts had an ECOG score of =<1. Pts received a median of 2 (1-4) treatment cycles and a median of 5 (1-10) DARA injections. Most common (> 2 pts) treatment emergent adverse events (TEAEs) were nausea (47%), diarrhea (33%), fatigue (33%), injection site erythema (20%), anemia (20%), and rash (20%). Dyspnea and peripheral edema were reported in 1 (7%) pt each. One grade 3/4 TEAE (hypertension; unrelated to treatment) and no serious TEAEs occurred. IRRs occurred in 2 (13.3%) pts (all grade 1). Additional data will be presented.
DARA-CyBorD is tolerable in pts with AL amyloidosis with a low IRR rate and no new safety signals. The limited incidence of dyspnea and peripheral edema indicate a low risk for volume overload. Randomization into ANDROMEDA has begun. organization:
Tufts Medical Center, USA; University of Athens School of Medicine, Greece; Alexandra General Hospital, Greece; Presbyterian Hospital and Vanderbilt Clinic, USA; Barbara Ann Karmanos Cancer Research Institute, USA; UMC Utrecht Cancer Center, Netherlands; Heidelberg University Hospital, Germany; University College London and the Royal Free London NHS Foundation Trust, United Kingdom; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Italy; University of Pavia, Italy read more